$KNSA

Cole G Bradley sold 3,673 shares of Kiniksa Pharmaceuticals International, plc (KNSA) at $81.43 ($0.30M total) on 2026-07-29.

Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.

Kiniksa Pharmaceuticals (KNSA) reported Q2 2026 results, led by ARCALYST net product revenue of $243.6M, up from $156.8M in Q2 2025. Q2 net income was $25.4M, or $0.30 per diluted share. FY 2026 ARCALYST guidance was raised to $980M-$995M. Pipeline updates include KPL-387 Phase 3 planning and KPL-1161 Phase 1 progress.

Kiniksa Pharmaceuticals International plc shares rose about 21% on Nasdaq after its Q2 results for ARCALYST (rilonacept) beat expectations and it raised 2026 guidance. Net product revenue was $243.6M, about 55% higher year over year. 2026 guidance increased to $980M-$995M from $930M-$945M. Kiniksa also reported Q2 net income of $25.4M and $525.9M cash, and is enrolling PASTORALE for KPL-387.

Kiniksa Pharmaceuticals International, plc (KNSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 knsa-20260728xex99d1.htm EX-99.1 Exhibit 99.1 ​ ​ ​ ​ Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST ® (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –

Biotech stocks outperformed the broader market this year as investors rotated into growth and as M&A activity picked up, according to a Wedbush interview on BNN Bloomberg. The report cites an $11 billion AbbVie deal for Apogee. Wedbush highlighted Kiniksa (Q revenue $214M; raised guidance), Monte Rosa (Phase 2 updates), and Scholar Rock (FDA PDUFA Sept. 30; revenue estimates $163M in 2027, $450M in 2028).

Kiniksa Pharmaceuticals International plc announced the resignation of its Chief Strategy Officer, Eben Tessari, effective May 15, 2026. Mr. Tessari will transition to a consulting and advisory role for the company's Science and Research Committee, assuaging concerns about abrupt leadership changes. The company emphasized that his departure was voluntary and not due to any disagreement with company operations or policies.

Kiniksa Pharmaceuticals International, plc director Barry D. Quart exercised options to acquire 13,099 Class A Ordinary Shares at $14.33 per share and subsequently sold them at a weighted average price of $50.10. This transaction was conducted under a pre-arranged Rule 10b5-1 plan, indicating a pre-planned liquidity event. Following these actions, Quart directly holds 12,546 shares and retains 13,237 fully vested share options.

Kiniksa Pharmaceuticals (KNSA) stock reached a 52-week high after reporting better-than-expected Q1 2026 earnings and raising its full-year outlook. The positive performance is attributed to strong sales of Arcalyst, its heart disease therapy, which is licensed from Regeneron (REGN).

Kiniksa Pharmaceuticals International, plc CFO Mark Ragosa exercised 2,694 Restricted Share Units (RSUs) on April 7, 2026, which converted into Class A Ordinary Shares. To cover tax obligations related to this vesting, 1,303 shares were withheld at $48.94 per share. Following these transactions, Ragosa directly holds 16,154 Class A Ordinary Shares, with no open-market sales occurring.